Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Transmission of MDR in primary HIV-1 infection
3. IQ and the genetic barrier
4. E-184V study
5. E-184V study design
6. Results: 3TC alone vs. treatment interruption
7. Lamivudine activity as MDR HIV-1 infection therapy
8. Characteristics of study subjects at entry
9. Presence of 184V mutation in the absence of 3TC
10. Level of viral load in the absence of 3TC
11. Partial treatment interruptions (change in viral load)
12. Phenotypic sensitivity to Tipranavir
13. Phenotypic resistance of multi-PI-resistant isolates
14. TPV resist studies (1)
15. TPV resist studies (2)
16. TPV resist studies (3)
17. Efficacy of TMC125
18. Time to virological failure
19. MONARK trial
20. MONARK trial results: HIV RNA levels
21. SPREAD trial: transmitted drug resistance
22. Transmitted drug resistance over time
23. MK-0518: potent activity of integrase inhibitor
24. MK-0518 vs. EFV: HIV RNA levels
25. Potential benefits of MVC (entry inhibitor)
26. Phase II trial of efficacy and safety of vicriviroc
27. Summary

Topics Covered

• Drug resistance in HIV disease can occur for each drug used in therapy
• Drug resistant forms of HIV can be sexually transmitted
• Drug resistance can be selected by antiviral drugs
• HIV mutations can interact with one another to affect phenotype
• Newer drugs in each class can work against resistant forms of HIV
• New drug classes continue to be developed

Links

Series:

• Retroviruses

Categories:

• Clinical Practice
• Immunology
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Infectious Diseases

Talk Citation

Wainberg, M. (2007, October 1). What to do in therapy in the face of HIV drug resistance? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/XJNT9019.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on October 28, 2018

Financial Disclosures

• Prof. Mark Wainberg has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.